🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

David Einhorn’s TEVA Holdings & Trades

First Buy
Q4 2023
Duration Held
9 Quarters
Largest Add
Q2 2025
+3.21 M Shares
Current Position
3.06 M Shares
$95.46 M Value

David Einhorn's TEVA Position Overview

David Einhorn (via Dme Capital Management, Lp) currently holds 3.06 M shares of Teva Pharmaceutical Industries Limited (TEVA) worth $95.46 M, representing 3.35% of the portfolio. First purchased in 2023-Q4, this medium-term investment has been held for 9 quarters.

Based on 13F filings, David Einhorn has maintained a strategic position in TEVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 3.21 M shares. Largest reduction occurred in Q4 2025, reducing 720,043 shares.

Analysis based on 13F filings available since 2013 Q2

David Einhorn's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time

Track share changes against reported price movement

Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by David Einhorn

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -720,043 Reduce 19.05% 3.06 M $31.21
Q2 2025 +3.21 M Add 565.04% 3.78 M $16.76
Q1 2025 +99,650 Add 21.27% 568,200 $15.37
Q4 2024 +143,700 Add 44.24% 468,550 $22.04
Q1 2024 +324,851 Add 0.00% 324,850 $14.11
Q4 2023 +268,470 New Buy 268,470 $10.44

David Einhorn's Teva Pharmaceutical Industries Limited Investment FAQs

David Einhorn first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q4 2023, acquiring 268,470 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

David Einhorn has held Teva Pharmaceutical Industries Limited (TEVA) for 9 quarters since Q4 2023.

David Einhorn's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q2 2025, adding 3,778,777 shares worth $63.33 M.

According to the latest 13F filing for Q4 2025, David Einhorn's firm, Dme Capital Management, Lp, owns 3,058,734 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $95.46 M.

As of the Q4 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 3.35% of David Einhorn's publicly disclosed stock portfolio, making it one of their key holdings.

David Einhorn's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 3,778,777 shares, as reported at the end of Q2 2025.